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Abstract
Background: There remains variability in both practice and evidence related to optimal initial empiric dosing strategies for vancomycin.
Objective: Our primary objective was to describe the percentage of obese patients receiving vancomycin doses consistent with
nomogram recommendations achieving targeted initial steady-state serum vancomycin concentrations. Secondary objectives were to
describe the primary endpoint in subgroups based on patient weight and estimated creatinine clearance, to describe the rate of
supratherapeutic vancomycin accumulation following an initial therapeutic trough concentration, and to describe the rate of
vancomycin-related adverse events.
Methods: This single-center, IRB-approved, retrospective cohort included adult patients ≥ 100 kilograms total body weight with a body
mass index (BMI) >30 kilograms/m2 who received a stable nomogram-based vancomycin regimen and had at least one steady-state
vancomycin trough concentration. Data collected included vancomycin regimens and concentrations, vancomycin indication, serum
creatinine, and vancomycin-related adverse events. Patients were divided into two cohorts by goal trough concentration: 10-15
mcg/mL and 15-20 mcg/mL.
Results: Of 325 patients screened, 85 were included. Goal steady-state concentrations were reached in 42/85 (49.4%) of total patients.
Conclusions: Achievement of initial steady-state vancomycin serum concentrations in the present study (approximately 50%) was
consistent with the use of published vancomycin dosing nomograms.
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INTRODUCTION
More than one-third of adults in the United States are
obese and consequently at a significantly increased risk for
heart disease, stroke, and type 2 diabetes.1 In addition to
these health implications, the physiologic changes from
obesity
also
impact
pharmacokinetic
and
pharmacodynamic properties of drugs. These changes can
impact both efficacy and toxicity, especially in
antimicrobials such as vancomcyin.2
Vancomycin is a tricyclic glycopeptide antibiotic commonly
used as therapy for infections caused by Gram-positive
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organisms,
most
notably
methicillin-resistant
Staphylococcus aureus (MRSA).3 Published adult dosing
recommendations for vancomycin in the general
population are 15 to 20 mg/kg per dose every 8 to 24 hours
(based upon total body weight [TBW] and estimated renal
function).4 However, such recommendations may be
inadequate in obese patients due to increases in
vancomycin clearance and volume of distribution.5 In
addition, when applied to obese patients, the large single
doses resulting from such weight-based recommendations
increase the risk of dose-related toxicities.5
Variability in both practice and lack of evidence related to
optimal initial dosing strategies for vancomycin exist.5 For
example, dosing based on TBW achieves target steadystate trough concentrations more frequently then when
based on ideal body weight (IBW).2 In contrast, one study5
demonstrated that use of adjusted body weight (ABW)
provided the best predictor to serum concentrations, and
another6 recommended using 45 to 65 mg/kg/day based on
IBW.5-6 In addition to weight-based dosing, published
dosing nomograms have also been extensively evaluated.7-9
Their efficacy in achieving initial goal trough concentrations
(10-20 mcg/mL) has been shown to range from 40-60% on
the initial regimen, but the majority excluded patients
weighing more than 120 kg or limited the maximum single
7-9
dose to 2 gms. Studies analyzing appropriate vancomycin
dosing and monitoring in obese patients have reported
variable success rates. In one, approximately 60% of initial
vancomycin
steady-state
concentrations
were
subtherapeutic (<10 mcg/mL), leading to increased risk of
resistance and treatment failure.8 Another concluded that
obese patients most often reached target trough
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concentrations when given 20-30 mg/kg/day based on
TBW.9
There has yet to be a consensus or guideline
recommendations for dosing and monitoring in obese
patients. At Duke University Hospital, a validated empiric
dosing nomogram for patients weighing 50-100 kg has been
in place since 2010. In order to fulfill an increasing and
unmet need, an empiric vancomycin dosing nomogram was
developed at Duke Regional Hospital (DRH) in 2016
targeting patients weighing 100 to 160 kg (see Appendix).
While we hypothesized this nomogram would provide
appropriate initial vancomycin dosing guidelines in this
population, it had not been previously evaluated. The
purpose of our study was to evaluate this newlyimplemented vancomycin dosing nomogram in achieving
goal steady-state trough concentrations for obese adult
patients.
METHODS
The primary objective of this single-center, retrospective
cohort study was to describe the percentage of obese
patients receiving initial vancomycin doses consistent with
nomogram recommendations achieving targeted initial
steady-state serum vancomycin concentrations. The
secondary objectives were to describe the primary
endpoint in subgroups based on patient weight and
estimated creatinine clearance (CrCl). We also sought to
describe the percentage of patients maintaining a target
steady-state trough concentration, on a consistent
regimen, for one subsequent level following an initial target
steady-state trough concentration to assess the rate of
accumulation. Lastly, patients were evaluated for
vancomycin-related adverse effects, including new-onset
kidney injury and Red Man syndrome.
This single-center, retrospective cohort study was approved
by the Duke University Health System Institutional Review
Board and conducted at DRH, a 369-bed community
hospital in Durham, NC. Patients >18 years-old, admitted to
a general medicine or surgery unit from December 1, 2015
to February 1, 2017 were included. Subjects who weighed
>100 kg and had a BMI of >30 kg/m2 who received at least
2 scheduled vancomycin doses following the appropriate
loading dose (per nomogram recommendations) were
included if at least one steady-state trough vancomycin
concentration (defined as following at least the third dose
of the regimen and drawn within 2 hours of the next
sequential dose) was measured. Patients were excluded for
any of the following: renal dysfunction (defined as an
estimated CrCl <10 mL/min), unstable renal function
(defined as a change in serum creatinine (SCr) of 0.5 mg/dL
or 50% reduction in estimated CrCl between initial dose
and time of subsequent trough measurement), moderate
to severe liver dysfunction at baseline (defined as aspartate
aminotransferase or alanine aminotransferase levels >two
times the upper limit of normal (ULN), or a total bilirubin
level >two times the ULN), ascites, burns (>20% total body
surface area), within 30 days of solid organ or
hematopoietic stem cell transplantation, had cystic fibrosis,
were patients in the critical care unit, or were pregnant.

Patients were identified utilizing the Duke Enterprise Data
Unified Content Explorer (DEDUCE). Separate admissions
for the same patient were counted as individual cases. Data
were collected using a Microsoft Access database and entry
form. Patient demographics collected included gender, age,
weight, height, BMI, and the presence of chronic kidney
disease (CKD). Other data collected included vancomycin
indication, vancomycin dosing regimens, and vancomycin
serum trough concentrations, dates, and collection times.
SCr and estimated CrCl at time of vancomycin initiation and
trough concentration of maintenance regimen utilizing a
modified Cockroft-Gault equation (removing weight and 72
from numerator and denominator, respectively).10 Of note,
in patients >70 years old, a SCr below 1 mg/dL was rounded
to 1 mg/dL to calculate CrCl. For initial loading doses,
patients received 25 mg/kg TBW unless they had impaired
renal function indicated by new-onset kidney injury or CKD
Stage IV or worse. In this case, patients were loaded with
20 mg/kg TBW. However, we incorporated our institution’s
policy of vancomycin dose capping at 2500 mg. For patients
with therapeutic serum trough concentrations that were
continued on the same regimen, SCr was collected again at
the time of the next trough concentration. Lastly, presence
of Red Man syndrome and new-onset kidney injury at the
time of concentration collection (defined as an increase in
SCr by 0.3 mg/dL or more within 48 hours, or an increase in
SCr to 1.5 times baseline or more within the last 7 days, or
urine output less than 0.5 mL/kg/h for 6 hours) was
collected.11 The institutional nomogram was developed
with the above in mind, utilizing traditional vancomycin
pharmacokinetic calculations including the Matzke
equation for the elimination rate constant. For patients
receiving multiple courses of vancomycin during a single
admission, only the first course was included in the study.12
Data Analysis
The primary endpoint (initial steady-state serum
vancomycin concentration within the indication-specific
target range) and patient demographics were characterized
using descriptive statistics. For the secondary objectives,
the endpoints utilized were percentage of therapeutic
trough concentrations in the pre-specified cohorts,
percentage of patients experiencing vancomycin
accumulation to a supratherapeutic level following an
initial therapeutic concentration, and percentage of
patients experiencing a vancomycin-related adverse event
such as new-onset kidney injury. Patients were cohorted by
CrCl (10-39 mL/min, 40-69 mL/min, 70-99 mL/min, and
100+ mL/min) and weight (100-119 kg, 120-139 kg, 140-159
kg, and 160+ kg).
RESULTS
Of 325 patients weighing over 100 kg and on vancomycin
identified and screened, 85 (26.2%) met inclusion criteria.
Patients were excluded for the following: doses were not
consistent with nomogram recommendations (n=168), no
trough concentration level (n=36), critical care unit status
(n=28), BMI <30 kg/m2 (5), and weight <100 kg at time of
vancomycin initiation (3). The study population was
predominantly male with an average age of 60 years.
Remaining subject demographics are summarized in Table
1. All subjects had an estimated CrCl > 30 mL/min and the
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Table 1. Baseline demographic characteristics of included subjects (by cohort)
Cohort
Parameter
10-15 mcg/mL
15-20 mcg/mL
All patients
(n=28)
(n=57)
(n=85)
Age, yr
56.1 (11.8)
57.5 (15.2)
56.9 (13.0)
Gender, n (Male:Female)
15:13
37:20
52:33
Weight, kg
133.2 (35.6)
122.0 (17.6)
125.1 (25.3)
2a
BMI, kg/m
44.8 (12.7)
39.5 (7.3)
40.9 (9.5)
b
CrCl , mL/min
98.8 (22.1)
72.7 (24.6)
81.3 (26.7)
Indications, n(%)
c
SSTI
26 (92.9)
17 (29.8)
43 (50.1)
Osteomyelitis
0
16 (28.1)
16 (18.8)
Sepsis
0
11 (19.3)
11 (12.9)
Pneumonia
0
6 (10.5)
6 (7.1)
Bacteremia
1 (3.6)
4 (7.0)
5 (5.9)
Intra-abdominal
0
3 (5.3)
3 (3.5)
Other
1 (3.6)
0
1 (1.2)
Vancomcyin regimen
1.5g Q12H
11
11
22 (25.9)
1.75g Q12H
5
10
15 (17.6)
2g Q12H
4
8
12 (14.1)
1.75g Q18H
0
8
8 (9.4)
1.25g Q8H
0
6
6 (7.1)
Other
8
14
22 (25.9)
Baseline renal disease
d
CKD Stage III-V
1 (3.6)
9 (15.8)
10 (11.8)
a. Body Mass Index b. Creatinine clearance in normalized Cockroft-Gault c. skin and soft tissue infections d.
Chronic Kidney Disease

mean CrCl was 81.3 mL/min. The majority of patients were
in the 15-20 mcg/mL goal trough cohort and were receiving
therapy for complicated skin and skin structure infections
(SSTI).
Goal steady-state trough concentrations were reached in
42 patients (49.4%) with 27 (47.4%) in the 15-20 mcg/mL
cohort and 15 (53.6%) in the 10-15 mcg/mL cohort. In the
total population, 24.7% had subtherapeutic levels at steady
state and 25.9% had supratherapeutic levels. There was
also a similar distribution of subtherapeutic levels and
supratherapeutic levels in each goal trough subgroup
(Figure 1). Trough levels ranged from 6.1-30.9 mcg/mL.
When this data was combined, 58 patients (68.2%) had
levels that fell in the 10-20 mcg/mL range.

When divided into pre-specified subgroups based on goal
trough concentrations, weight, and estimated CrCl (Table
2), the majority of patients fell into the 100-119 kg groups
(n= 47, 55%). There were a limited number of patients >140
kg (n=13, 15%), and only 28 patients had an estimated CrCl
<70 mL/min. 69% of the pre-specified subgroups containing
at least one patient in the 15-20 mcg/mL goal cohort and
67% of the subgroups in the 10-15 mcg/mL cohort had
mean trough concentrations at goal, respectively (Table 2).
Notably, 16/21 (76%) of total patients with subtherapeutic
trough concentrations had an estimated CrCl >70 mL/min.
However, there were more patients in these subgroups and
the majority still achieved goal trough concentrations
(n=30, 52.6%). There was a noticeably higher rate of

Figure 1. Number achieving trough concentrations based on target trough concentration goal.
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Table 2. Subgroup analysis – average trough concentration (SD), mcg/mL
10-15 mcg/mL goal
100-119 kg
120-139 kg
10-39 mL/min
N/A
N/A
40-69 mL/min
17.0 (3.6)
22.8 (0)*
70-99 mL/min
14.4 (5.7)
11.5 (0)*
> 100 mL/min
10.7 (2.9)
9.8 (3.6)
15-20 mcg/mL goal
100-119 kg
120-139 kg
10-39 mL/min
18.6 (2.4)
16.1 (0)*
40-69 mL/min
17.2 (4.8)
18.8 (4.3)
70-99 mL/min
16.9 (5.6)
18.7 (4.0)
> 100 mL/min
12.6 (3.0)
23.2 (2.1)*
*<2 patients represented in the subgroup

patients reaching initial supratherapeutic trough
concentrations in the CrCl <70 mL/min subgroups
compared to those with a CrCl >70 mL/min (35.7% vs.
19.3%).
Very few patients were continued on the same vancomycin
regimen following the achievement of a target trough
concentration long enough to check a second
concentration (n=11, 26.2%). Of these 11 patients, 5
experienced accumulation to a supratherapeutic trough
concentration on the subsequent level, with a mean (SD)
time to next level of 2.9 (SD=1.2) days. However, 3 (60%) of
these patients developed new-onset kidney injury between
the first and second concentration drawn.
No patients had to have vancomycin discontinued due to
adverse events. Five patients experienced new-onset
kidney injury during treatment and one patient was
reported to have Red Man syndrome which was noted to
improve when the infusion was administered at a slower
rate. No other drug-related adverse effects were reported.
DISCUSSION
The results of our study found that our nomogram achieved
target trough concentrations nearly 50% of the time. Prior
attempts to utilize nomograms to provide initial dosing
recommendations for vancomycin in obese patients have
been met with variable success. One protocol employed a
20 mg/kg loading dose followed by 10 mg/kg/dose (based
on TBW) every 12-24 hours in morbidly obese adults (BMI
>40).8 This dose was chosen based on previous findings
that demonstrated a high rate of supratherapeutic
concentrations with higher doses.8 With this decreased
dose, initial goal trough concentrations were achieved in
35.4% of patients, while subtherapeutic troughs occurred in
56.3% and supratherapeutic troughs in only 8.3% of
patients.8 Another recent retrospective study concluded
that obese (BMI 30-40) and morbidly obese (BMI >40)
patients most often reached target trough concentrations
when given 20-30 mg/kg/day based on TBW.9 However,
this study had limitations which included a high rate of
subtherapeutic trough concentrations (48%) and no loading
doses were given.9
Compared to the aformentioned studies and another by
Morrill et al, which utilized a similar dosing strategy and
yielded 48% subtherapeutic initial trough levels, our study
had a more even distribution of non-therapeutic trough
concentrations.7-9 Approximately 25% of patients had
subtherapeutic trough levels with no level being lower than
6 mcg/mL, while another 25% of patients had
supratherapeutic levels with only one level being greater

140-159 kg
N/A
N/A
N/A
14.5 (0)*
140-159 kg
N/A
19.9 (0)*
11.5 (0)*
17.8 (0)*

> 160 kg
N/A
N/A
13.8 (1.6)
14.8 (3.8)
> 160 kg
N/A
14.2 + 6.1*
N/A
15.4 (0)*

than 30 mcg/mL (30.9). While we had a slightly higher rate
of new-onset kidney injury during therapy compared to the
previous trials, all patients experiencing kidney injury were
on concomitant nephrotoxic medications including
piperacillin-tazobactam, thiazide diuretics, and intravenous
acyclovir.8,9,13
The results of this study fall within the range of results in
previous
studies
evaluating
vancomycin
dosing
nomograms, achieving goal steady-state trough
concentrations nearly 50% of the time.7,14-16 Unlike the
majority of previous studies analyzing vancomycin
nomograms, this study only included obese patients
weighing at least 100 kg with no maximum weight.4-7,14-16
When looking at the limited previous literature on
vancomycin dosing in obese patients, our nomogram
appears to be safe and similarly effective. Notable studies
analyzing vancomycin dosing in obese patients have utilized
protocols or nomograms that have based dosing on
simplified mg/kg calculations paired with estimated renal
function for determining frequency.8,9,13 Our nomogram
was developed utilizing traditional pharmacokinetic
calculations for each subgroup using TBW for volume of
distribution calculations and normalized CrCl which
ultimately leads to a lower estimation of drug clearance in
these patients. Utilizing this method of dosing, we
predicted that our patients would receive large enough
doses without experiencing toxic levels as a result of too
frequent dosing.
This was also the first study to our knowledge to collect
data on vancomycin accumulation in the real-world obese
patient population. While our data is limited to 11 patients
who were continued on their original therapeutic regimen
long enough to receive a second trough level, it does reveal
a concern for drug accumulation in this population. Nearly
half (45%) of these patients experienced a subsequent
supratherapeutic level following an initial therapeutic
trough concentration and no change in dosing regimen. It is
important to note that 3 of these patients had significant
increases in SCr levels near the time of the follow-up level.
Further studies are needed in this area to assess
vancomycin adjustments in these patients to avoid
potentially toxic accumulation.
Our study was not without limitations. Though our
nomogram was designed using common calculations
utilized in clinical practice, there are potential limitations
with the pharmacokinetics of using the standard Vd,
Matzke equation, and SCr rounding in the obese
population.12 However, there is no current consensus on
the best method. AUC-based monitoring has also shown
promising data, but until more implementable evidence
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exists, many institutions will continue traditional
vancomycin dosing.17 With no active or historical
comparator, we were only able to report descriptive
statistics limiting ability to show any association with
patient specific factors and vancomycin concentrations. We
were also limited to a small sample size. Although over 300
patients were screened for inclusion, pharmacists were not
required to utilize the nomogram during the evaluation
period which led to many exclusions. We also excluded
patients in the critical care unit per the institution’s
pharmacokinetic policy which limits extrapolation to these
patients. This limited sample size and utilization also
inhibited our ability to truly evaluate the effectiveness of
our nomogram in patients with poor CrCl and those
weighing over 140 kg. Lastly, we did not evaluate clinical
outcomes of the patients.

concentrations
(25%
subtherapeutic
and
25%
supratherapeutic). Our study also added evidence for the
risk vancomycin accumulation in continued dosing in this
patient population. Future plans should include identifying
patient-specific factors associated with non-therapeutic
trough levels in the obese patient population and
developing accurate pharmacokinetic models for this
population.
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